Pancreatic Cancer Research

ResearcherBrooke Army Medical CenterActive in the last 2 years

Timothy J. Vreeland

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4593-7502; OpenAlex author ID A5065391640. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  2. Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. Last author DOI 10.1002/jso.27466↗
  3. The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy. Last author DOI 10.1002/jso.27689↗
  4. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000005184↗
  5. Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12908-z↗
  6. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-13758-z↗
  7. Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. Last author DOI 10.1245/s10434-022-11800-0↗
  8. ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-022-11878-6↗
  9. Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.2147/ott.s311661↗
  10. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… Co-author DOI 10.1097/mpa.0000000000001345↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel William Nelson · 7 shared papers, 2021–2024 · strength 1.22
  2. Elizabeth L. Carpenter · 6 shared papers, 2022–2024 · strength 1.10
  3. Alexandra M. Adams · 6 shared papers, 2021–2024 · strength 1.00
  4. Anne E. O’Shea · 5 shared papers, 2021–2024 · strength 0.85
  5. Phillip M. Kemp Bohan · 4 shared papers, 2022–2024 · strength 0.69
  6. Patrick M. McCarthy · 4 shared papers, 2021–2024 · strength 0.62
  7. Matthew H. G. Katz · 4 shared papers, 2019–2025 · strength 0.56
  8. Ching-Wei David Tzeng · 3 shared papers, 2019–2023 · strength 0.41
  9. Holly V. Spitzer · 2 shared papers, 2023 · strength 0.37
  10. Franklin A. Valdera · 2 shared papers, 2024 · strength 0.36
  11. Timothy Eric Newhook · 2 shared papers, 2023–2024 · strength 0.34
  12. Robert Connor Chick · 2 shared papers, 2022–2024 · strength 0.31
  13. Eugene Jon Koay · 2 shared papers, 2023–2025 · strength 0.30
  14. Robert W. Krell · 2 shared papers, 2021–2022 · strength 0.26
  15. Laura R. Prakash · 2 shared papers, 2019–2023 · strength 0.23
  16. Michael P. Kim · 2 shared papers, 2019–2023 · strength 0.23
  17. Jeffrey E. Lee · 2 shared papers, 2019–2023 · strength 0.23
  18. Davendra P. S. Sohal · 1 shared paper, 2025 · strength 0.15
  19. Andrew H. Ko · 1 shared paper, 2025 · strength 0.15
  20. Alok A. Khorana · 1 shared paper, 2025 · strength 0.15
  21. Steve Walston · 1 shared paper, 2025 · strength 0.15
  22. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.15
  23. P. A. Philip · 1 shared paper, 2025 · strength 0.15
  24. Melissa Ellen Hogg · 1 shared paper, 2025 · strength 0.15
  25. Matthew J. Arango · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.